Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
2.
J R Soc Interface ; 11(96): 20140233, 2014 Jul 06.
Article in English | MEDLINE | ID: mdl-24789561

ABSTRACT

Urological reconstructive surgery is sometimes hampered by a lack of tissue. In some cases, autologous urothelial cells (UCs) are not available for cell expansion and ordinary tissue engineering. In these cases, we wanted to explore whether autologous mesenchymal stem cells (MSCs) from bone marrow could be used to create urological transplants. MSCs from human bone marrow were cultured in vitro with medium conditioned by normal human UCs or by indirect co-culturing in culture well inserts. Changes in gene expression, protein expression and cell morphology were studied after two weeks using western blot, RT-PCR and immune staining. Cells cultured in standard epithelial growth medium served as controls. Bone marrow MSCs changed their phenotype with respect to growth characteristics and cell morphology, as well as gene and protein expression, to a UC lineage in both culture methods, but not in controls. Urothelial differentiation was also accomplished in human bone marrow MSCs seeded on a three-dimensional poly(ε-caprolactone) (PCL)-collagen construct. Human MSCs could easily be harvested by bone marrow aspiration and expanded and differentiated into urothelium. Differentiation could take place on a three-dimensional hybrid PCL-reinforced collagen-based scaffold for creation of a tissue-engineered autologous transplant for urological reconstructive surgery.


Subject(s)
Bone Marrow Cells/cytology , Mesenchymal Stem Cells/cytology , Tissue Engineering/methods , Urothelium/cytology , Cell Culture Techniques , Cell Differentiation , Collagen , Humans , Plastic Surgery Procedures , Tissue Scaffolds , Transplantation, Autologous
3.
Placenta ; 32 Suppl 4: S285-90, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21575989

ABSTRACT

The International Placenta Stem Cell Society (IPLASS) was founded in June 2010. Its goal is to serve as a network for advancing research and clinical applications of stem/progenitor cells isolated from human term placental tissues, including the amnio-chorionic fetal membranes and Wharton's jelly. The commitment of the Society to champion placenta as a stem cell source was realized with the inaugural meeting of IPLASS held in Brescia, Italy, in October 2010. Officially designated as an EMBO-endorsed scientific activity, international experts in the field gathered for a 3-day meeting, which commenced with "Meet with the experts" sessions, IPLASS member and board meetings, and welcome remarks by Dr. Ornella Parolini, President of IPLASS. The evening's highlight was a keynote plenary lecture by Dr. Diana Bianchi. The subsequent scientific program consisted of morning and afternoon oral and poster presentations, followed by social events. Both provided many opportunities for intellectual exchange among the 120 multi-national participants. This allowed a methodical and deliberate evaluation of the status of placental cells in research in regenerative and reparative medicine. The meeting concluded with Dr. Parolini summarizing the meeting's highlights. This further prepared the fertile ground on which to build the promising potential of placental cell research. The second IPLASS meeting will take place in September 2012 in Vienna, Austria. This meeting report summarizes the thought-provoking lectures delivered at the first meeting of IPLASS.


Subject(s)
Fetal Stem Cells/cytology , Placenta/cytology , Female , Fetus , Humans , Pregnancy
4.
Mol Hum Reprod ; 16(7): 472-80, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20200148

ABSTRACT

Transplacental passage of circulating first-trimester fetal mesenchymal stem cells (fMSC) raises the prospect of harvesting fetal cells in maternal blood. Despite high sensitivity in model systems, negative selection and culture strategies yield fMSC only rarely in post-termination maternal blood. The different adhesion molecule profile of fMSC to competitor maternal cell types suggests that improved positive selection strategies may facilitate non-invasive prenatal diagnosis. We aimed to identify surface antigens specific to fMSC and not maternal peripheral blood lymphocytes (PBL), using genome-wide analysis of actively expressed transcripts. Maternal PBL and fMSC cultured from first-trimester blood, liver and bone marrow were assessed for global gene expression by Affymetrix U133Plus2.0 arrays. Data were analysed using Affymetrix GCOS01.2. Transcripts present in all fMSC (n = 9) but absent in all PBL samples (n = 3) were selected for further analysis of cell-surface membrane molecules by RT-PCR and immunocytochemistry. Of 1544 genes expressed in fMSC and not maternal PBL, filtering for cell-surface molecules yielded 159 genes. Of these, 29 had a mean expression ratio of >300 (P < 0.001), which represented 18 unique genes, and their positive expression in all fMSC samples was confirmed by RT-PCR. Candidates for non-invasive prenatal diagnosis were chosen for further analysis by immunocytochemistry. Surface expression of OSMR and COL1 proteins on all fMSC, but no maternal PBL was confirmed. Identification of novel surface antigens on circulating human fMSC and not maternal PBL facilitates positive selection strategies for isolating fMSC for non-invasive prenatal diagnosis.


Subject(s)
Antigens, Surface/metabolism , Fetus/cytology , Mesenchymal Stem Cells/cytology , Mesenchymal Stem Cells/metabolism , Prenatal Diagnosis/methods , Cells, Cultured , Female , Humans , Immunohistochemistry , Oligonucleotide Array Sequence Analysis , Pregnancy , Reverse Transcriptase Polymerase Chain Reaction
5.
Cytotherapy ; 10(2): 174-81, 2008.
Article in English | MEDLINE | ID: mdl-18368596

ABSTRACT

BACKGROUND: It has been shown recently that human umbilical cord perivascular cells (HUCPVC) are bio-equivalent to bone marrow-derived mesenchymal stromal cells (BM-MSC) in their mesenchymal differentiation and marker expression. HUCPVC populations provide high yields of rapidly proliferating mesenchymal progenitor cells. The question we wished to address, in two independent laboratory studies, was whether HUCPVC exhibit a similar in vitro immunologic phenotype to that of BM-MSC. METHODS: HUCPVC were isolated by physical extraction of umbilical vessels followed by enzymatic digestion of the perivascular cells, and lymphocytes were obtained from heparinized human peripheral blood. Experimental evaluations were lymphocyte proliferation in HUPCVC or BM-MSC co-cultures with peripheral blood lymphocytes (PBL), mixed lymphocyte cultures (MLC) containing BM-MSC or HUCPVC, CD25 and CD45 expression in co-cultures containing HUCPVC, and finally lymphocyte proliferation in TransWell MLC with HUCPVC. RESULTS: Both HUCPVC and BM-MSC showed no significant increase in proliferation of lymphocytes when co-cultured. The addition of 10% HUCPVC or BM-MSC significantly reduced proliferation of PBL in one-way MLC. Upon inclusion of HUCPVC with activated T-cell lines, the expression of both CD25 and CD45 showed a significant decrease. HUCPVC were able to reduce lymphocyte cell numbers significantly when separated with a membrane insert. DISCUSSION: HUCPVC are not alloreactive and exhibit immunosuppression in vitro. Lymphocyte activation is significantly reduced in the presence of HUCPVC, and the immunosuppressive effect of HUCPVC is due, in part, to a soluble factor. Thus HUCPVC shows a similar immunologic phenotype to BM-MSC.


Subject(s)
Umbilical Cord/blood supply , Umbilical Cord/immunology , Analysis of Variance , Cell Count , Cell Line , Cell Proliferation , Coculture Techniques , Humans , Interleukin-2 Receptor alpha Subunit/metabolism , Leukocyte Common Antigens/metabolism , Lymphocyte Activation , Lymphocyte Culture Test, Mixed , T-Lymphocytes/cytology , Umbilical Cord/cytology
6.
Scand J Immunol ; 60(3): 307-15, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15320889

ABSTRACT

Mesenchymal stem cells (MSC) are immunomodulatory and inhibit lymphocyte proliferation. We studied surface expression of lymphocyte activation markers and secreted cytokines, when lymphocytes were activated in the presence of MSC. MSC suppressed the proliferation of phytohaemagglutinin (PHA)-stimulated CD3+, CD4+ and CD8+ lymphocytes. MSC significantly reduced the expression of activation markers CD25, CD38 and CD69 on PHA-stimulated lymphocytes. Mixed lymphocyte culture (MLC) supernatants containing MSC suppressed proliferation of MLC and PHA-stimulated lymphocytes dose-dependently. MSC secrete osteoprotegerin (OPG), but not hepatocyte growth factor (HGF) or transforming growth factor-beta (TGF-beta). Stromal-cell-derived factor-1 (SDF-1) is not expressed on the cell surface. A recent report suggested that T-cell suppression by MSC is mediated by HGF and TGF-beta. MSC suppression was not restored by the addition of neutralizing antibodies against SDF-1, OPG, HGF or TGF-beta, alone or in combination. Addition of guanosine to PHA-stimulated lymphocyte cultures containing MSC did not affect lymphocyte proliferation. The immunosuppressive effects of cyclosporine and MSC did not interfere, when present in the cultures of PHA-activated lymphocytes. In summary, human MSC suppress proliferation of both CD4+ and CD8+ lymphocyte and decrease the expression of activation markers.


Subject(s)
ADP-ribosyl Cyclase/metabolism , Antigens, CD/metabolism , Lymphocytes/metabolism , Mesenchymal Stem Cells/metabolism , Phytohemagglutinins/immunology , Receptors, Interleukin-2/metabolism , ADP-ribosyl Cyclase 1 , Biomarkers , CD3 Complex/immunology , CD3 Complex/metabolism , Humans , Lymphocytes/immunology , Membrane Glycoproteins , Mesenchymal Stem Cells/immunology
7.
Bone Marrow Transplant ; 32(3): 265-72, 2003 Aug.
Article in English | MEDLINE | ID: mdl-12858197

ABSTRACT

Adult mesenchymal stem cells (MSCs) have been suggested to decrease lymphocyte proliferation in vitro. We hypothesised that foetal MSCs (fMSCs) would have an immunosuppressive effect on allograft responses in vitro. Human MSCs were isolated and cultured from first-trimester foetal livers and characterised by flow cytometry. fMSC stained positive for CD29, CD44, CD166, CD105, SH-3 and SH-4, and negative for CD14, CD34 and CD45. When plated on adipogenic, chondrogenic and osteogenic media, fMSC differentiated into the respective cell lineage. Compared to adult MSC (aMSC), the proliferative capacity of fMSC was higher. Mitogen stimulation of PBL was inhibited by fMSC. The greatest inhibition (78%) was seen when 30,000 fMSCs were added to 150,000 lymphocytes stimulated by phytohaemagglutinin. Adult and fMSCs were added to mixed lymphocyte cultures (MLC) containing peripheral blood lymphocytes or foetal liver cells. Unlike aMSC, fMSCs did not inhibit MLC. fMSC could be culture-expanded several million folds with no loss of phenotype characteristics, which makes them ideal for ex vivo expansion. fMSC inhibit lymphocyte proliferation induced by mitogens, but not alloreactivity as measured by MLC.


Subject(s)
Immunity, Cellular , Liver/cytology , Mesenchymal Stem Cells/immunology , Adolescent , Adult , Cell Culture Techniques/methods , Cell Differentiation , Child , Coculture Techniques , Fetus/cytology , Humans , Immunophenotyping , Liver/embryology , Lymphocyte Culture Test, Mixed , Lymphocytes/cytology , Lymphocytes/immunology , Mesenchymal Stem Cells/cytology , Middle Aged , Mitogens/pharmacology
8.
Vard Nord Utveckl Forsk ; 16(1): 4-10, 1996.
Article in Swedish | MEDLINE | ID: mdl-9555521

ABSTRACT

The aim of the article is to describe experiences from a project on quality assurance of nursing care in a county hospital. Assessment and improvement of the quality of care were mainly based on an earlier developed modified Swedish version of the Rush Medicus Nursing Process Quality Monitoring Instrument (RMI-MSV). Two hundred and forty patients and 57 registered nurses (RNs) representing surgical, medical and orthopaedic care units participated in the study, which was divided into two quality assessment occasions. An experiment-control design was used with intervention to the experiment units after the first quality assessment occasion. All the E-units improved their quality levels in almost all main areas in the second assessment occasion. The E-units together in relation to the C-units together obtained statistically significant improvements (p < 0.05) in the main area concerning documentation (E-units minus C-units occasion 2 minus occasion 1). The overall experience is that the RMI-MSV can be used for quality assurance of nursing care in a Swedish acute hospital, but needs to be further refined.


Subject(s)
Nursing Care/standards , Quality Assurance, Health Care/methods , Acute Disease/nursing , Humans , Internal Medicine , Nursing Evaluation Research/methods , Nursing Records/standards , Orthopedic Nursing/standards , Perioperative Nursing/standards , Reproducibility of Results , Sweden
9.
Int J Nurs Stud ; 32(3): 277-87, 1995 Jun.
Article in English | MEDLINE | ID: mdl-7665316

ABSTRACT

An instrument for measuring the concept of good care, in relation to the Swedish Health and Medical Services Act, has been developed and tested in short-term care. The instrument comprises 14 statements on good care. The construct validity was estimated by factor analysis based on the results from 240 patients. Five factors explained 62% of the variance of the 14 variables and covered the following areas: information, security, accessibility, continuity, and influence and respect. Patients (n = 240) and registered nurses (n = 57) showed differences in estimations of the concept of good care on all factors. There were only minor differences, however, within the patient group and the nursing group, respectively, on comparing the two samples. The instrument needs further testing in different care conditions.


Subject(s)
Nursing Audit/methods , Nursing Care/standards , Quality of Health Care/legislation & jurisprudence , Adult , Aged , Attitude of Health Personnel , Attitude to Health , Factor Analysis, Statistical , Female , Humans , Male , Nursing Care/psychology , Nursing Evaluation Research , Reproducibility of Results , Surveys and Questionnaires/standards , Sweden
10.
Int J Qual Health Care ; 6(1): 77-83, 1994 Mar.
Article in English | MEDLINE | ID: mdl-7953209

ABSTRACT

A modified Swedish version of the Rush Medicus Nursing Process Quality Monitoring Instrument (RMI-MSV) has been tested within surgical, medical and orthopedic units in a county hospital. Three units, one from each area, were randomized as experimental (E) units and three units as control (C) units. Two measurements, comprising 20 patients and five registered nurses in each unit, were carried out with an interval of 6 months. All the E units received feedback on the first measurement and one unit received special intervention concerning the main objective dealing with documentation. The E units tended to show greater improvements than the C units concerning most of the six main objectives included in the instrument. However, the objective dealing with documentation was the only one presenting a statistically significant greater improvement in E units compared with C units (p = 0.045). The effects obtained supported the evidence for validity of the RMI-MSV. The RMI-MSV was found to be sensitive to changes and appropriate for quality assessment. Further research is needed to develop non-situation-related factors which influence the quality of nursing care.


Subject(s)
Nursing Process , Nursing Service, Hospital/standards , Quality Assurance, Health Care , Adolescent , Adult , Aged , Aged, 80 and over , Female , Hospital Units/standards , Humans , Male , Methods , Middle Aged , Outcome and Process Assessment, Health Care , Sweden
SELECTION OF CITATIONS
SEARCH DETAIL
...